menu
    • menu

    Company profile for Ossianix

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    OSSIANIX, INC is a privately held pre clinical company that develops Biotherapeutic products using the highly versatile single domain VNAR antibody from the shark. The attractive biological and biophysical properties of the VNAR structure allows the rapid delivery of exquisitely high-affinity products to multiple target classes that have proven difficult or impossible by standard antibody approaches or alternative scaffolds. T...
    OSSIANIX, INC is a privately held pre clinical company that develops Biotherapeutic products using the highly versatile single domain VNAR antibody from the shark. The attractive biological and biophysical properties of the VNAR structure allows the rapid delivery of exquisitely high-affinity products to multiple target classes that have proven difficult or impossible by standard antibody approaches or alternative scaffolds. The platform is also attractive for generating bispecific antibodies that can be engineered with ease to develop products with differentiated features in diseases of high unmet need. Ossianix has also developed highly inn

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ossianixunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Stevenage Bioscience Catalyst, Gunnels Wood Rd, Stevenage, Hertfordshire, SG1...
    Telephone
    Telephone
    +44 (0)1438906821
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ossianix.co.uk/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ossianix/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Attralus &Ossianix Announce an Option and License Agreement using the TXP1
    Attralus &Ossianix Announce an Option and License Agreement using the TXP1

    17 Nov 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/11/17/2558010/0/en/Attralus-and-Ossianix-Announce-an-Option-and-License-Agreement-using-the-TXP1-Brain-Shuttle-for-Targeted-Delivery-of-AT-04-a-Pan-Amyloid-Removal-Therapeutic-for-Neurodegenerative-D.html

    GLOBENEWSWIRE
    17 Nov 2022
    Share Share
    Ossianix Announces Publication of Data on Shark VNAR Antibodies for COVID
    Ossianix Announces Publication of Data on Shark VNAR Antibodies for COVID

    10 Jun 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/correction-ossianix-announces-publication-of-positive-preclinical-data-on-neutralizing-sars-cov-2-infection-with-a-panel-of-single-domain-shark-vnar-antibodies-301310135.html

    PRNEWSWIRE
    10 Jun 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search